HOME Top Market Reports Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017

Protein Engineering Market [Products (Monoclonal Antibody, Insulin Analog, Modified EPO), Technology (Sequential Modification, Glycosylation, PEGylation), and Applications (Therapeutics, Diagnostics, Research)] - Global Forecast to 2017

By: marketsandmarkets.com
Publishing Date: March 2013
Report Code: BT 1358

Discount on Reports  

  Speak to Analyst Enquiry Before Buying
 
purchase report
download pdf  request for customisation


Proteins exhibit high specificity and less immunogenicity and are widely used as therapeutic agents in the treatment of various disorders and diseases. There are more than 200 protein-based products currently being marketed; 90% of them are used as therapeutics. In order to improve their clinical potential, second generation recombinants are being developed, each exhibiting improved efficiency and potency depending on their applications.

The global market (2012-2017) report analyses the market by technology, products, applications, and geography. It also includes recent technology trends, patents, and funding analysis. In addition, it also covers factors driving and restraining the growth of the market and market scenario in the U.S., Europe, Asia, and Rest of the World (RoW).

The protein engineering market is driven by the need for drugs with improved efficiency and specificity, technological capabilities, rise of antibody based drugs, and steady growth in the therapeutic market. With growing incidences of cancer, autoimmune disorders, and infectious disease, spurt of new opportunities for growth of the market is expected by the end of this decade. However, development costs, stringent regulatory issues, and risk of failure of the drug in the testing phase restraints the growth of the market. Further, the availability of generics and patent infringements is posing a threat to the market.

The global market is expected to grow at a CAGR of 10.9%; this growth is majorly fuelled by monoclonal antibodies, which is the fastest growing segment in therapeutics. The use of monoclonal antibodies in therapeutics such as oncology, auto immune and inflammatory diseases are expected to increase during the forecast period. Chinas growing interest in research of monoclonal antibodies is expected to increase market share further. The market is likely to face competition from the entry of generics; however, with many therapeutic proteins in the pipeline, the market is expected to grow exponentially. Insulin analogs, which are more efficient than the recombinant insulin, are also a contributing factor for growth of the market. Diagnostics is another segment in focus; monoclonal antibodies are being used extensively in diagnostics and in assays for research.

The report also profiles leading participants of the industry with their recent developments and other strategic industry activities. These include Genentech (U.S.), Amgen (U.S.), Roche (Switzerland), Eli Lilly (U.S.), Novartis (Switzerland), GlaxoSmithKline (U.K.), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Merck (U.S.), Pfizer (U.S.), Sanofi (France), Affymax (U.S.), Biogen Idec, (U.S.), Medimmune (U.S.) Affimed (Germany), and Obodies (New Zealand).

Scope of the Report

This technical report categorizes the market for protein engineering by geography, applications, products, and technology, forecasting the market revenue by analyzing current and future trends in therapeutics and diagnostics.These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

Global Protein engineering, by Technology

  • Sequence modification
  • Glycosylation
  • Pegylation
  • Display technologies
  • Humanization technology
  • Hybrid technology
  • Transgenic mice

Global Protein engineering, by Product

  • mAb
  • Insulin
  • Others
  • EPO
  • Diagnostics
  • Research

Geographic Analysis

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • France
    • Germany
    • Italy
  • Asia
    • Indonesia
    • India
    • China
    • South Korea
  • Rest of the World (RoW)
    • Japan
    • Australia

Table Of Content

1 Introduction  (Slide No. 18 - 23)
 
1.1 Key Take- Aways       
  1.2 Assumptions       
  1.3 Report Scope       
  1.4 Research Methodology       
  1.5 Key Data Points From Primary And Secondary Sources       
         
2 Executive Summary   (Slide No. 24 - 27)
         
3 Protein Engineering Technologies – Landscape Analysis   (Slide No. 28 - 45)

  3.1 Technology - Introduction       
  3.2 Technology – Evolution       
  3.3 Market Segmentation       
  3.4 Protein And Antibody Engineering Technologies – Overview       
      3.4.1 Sequence Modification      
      3.4.2 Glycosylation      
      3.4.3 Pegylation      
      3.4.4 Display Technologies      
      3.4.5 Humanization Technology      
      3.4.6 Hybrid Technology      
      3.4.7 Production Systems      
      3.4.8 Mapping Of Protein Production Systems      
      3.4.9 Emerging Production Systems      
  3.5 Protein Engineering – Technology Value Chain Analysis       
         
4 Applications   (Slide No. 46 - 54)
 4.1 Therapeutic Development – Overview        
      4.1.1 Insulin Analogs      
      4.1.2 Monoclonal Antibodies      
      4.1.3 Therapeutic Development - Erythropoietin & Others      
  4.2 Diagnostics       
  4.3 Research – Meganuclease Engineering / ZFP & TALENS Engineering         
         
5 Market Landscape Analysis    (Slide No. 55 - 92)
  5.1 Global Protein Engineering Market Forecast        
      5.1.1 Introduction      
      5.1.2 Global Market Forecast, By Geography      
      5.1.3 Global Market Forecast, By Product      
      5.1.4 Global Market Forecast, By Application      
      5.1.5 Global Market Forecast, By Technology      
  5.2 Market Dynamics - Overview       
      5.2.1 Drivers – Description       
      5.2.2 Drivers’ Impact – Timeline       
      5.2.3 Restraints – Description       
      5.2.4 Restraints Impact – Timeline       
      5.2.5 Opportunities – Description       
      5.2.6 Threats – Description       
      5.2.7 Pestle Analysis       
  5.3 Market Segmentation, By Product       
      5.3.1 Insulin Analogs      
            5.3.1.1 Insulin Analog Market     
            5.3.1.2 Insulin Analog Market, By Geography     
            5.3.1.3 Market Share Analysis     
      5.3.2 Modified EPO      
            5.3.2.1 Modified EPO Market     
            5.3.2.2 Modified EPO Market, By Geography     
      5.3.3 Monoclonal Antibodies (MAB)      
            5.3.3.1 Monoclonal Antibodies Market     
            5.3.3.2 Monoclonal Antibodies Market, By Geography     
            5.3.3.3 Monoclonal Antibodies Market, By Application     
            5.3.3.4 Major Products In The Market     
  5.4 Other Proteins       
      5.4.1 Other Proteins Market      
      5.4.2 Other Proteins Market, By Geography      
      5.4.3 Diagnostic Proteins, By Geography      
         
6 Geographic Analysis   (Slide No. 93 - 100)
  6.1 North America       
  6.2 Europe       
  6.3 Asia       
  6.4 Row       
         
7 Technology And Product Portfolio   (Slide No. 101 - 105)
  7.1 Proprietary Technology Platforms       
  7.2 Product Pipeline Analysis Of Key Players       
         
8 Competitive Landscape   (Slide No. 106 - 111)
  8.1 Introduction       
  8.2 Porter’s Five Force Analysis       
  8.3 Mergers & Acquisitions, 2009 – 2012       
  8.4 Partnerships & Collaborations, 2012 - 2013       
  8.5 New Product Launch, 2010 – 2012       
         
9 Analyst Insights And Recommendation   (Slide No. 112 - 114)
  9.1 Strategic Recommendations        
         
10 Company Profiles   (Slide No. 115 - 146)
  10.1 Genentech, Inc.       
  10.2 Amgen, Inc.       
  10.3 Biogen Idec, Inc.       
  10.4 Novartis Ag       
  10.5 Glaxo Smithkline Plc       
  10.6 Eli Lilly & Co       
  10.7 Bristol Myers Squibb Co.       
  10.8 Johnson & Johnson        
  10.9 Merck & Co., Inc.       
  10.10 Sanofi        
  10.11 Pfizer, Inc.       
  10.12 Regeneron Pharmaceuticals, Inc.        
  10.13 Eleven Biotherapeutics (U.S.)       
  10.14 Toolgen, Inc. (Korea)       
  10.15 Dna2.0, Inc. (U.S.)       
  10.16 Avidbiotics Corp. (U.S.)       
  10.17 Sigma-Aldrich Corp. (U.S.)       
  10.18 Xencor Inc.        
  10.19 Morphosys       

 

List Of Tables (11 Tables)           
           
Table - 1  Global Protein Engineering Market Revenue, 2012 – 2017 ($Billion)   
Table - 2  Global Market, By Geography, 2012 – 2017 ($Billion)  
Table - 3  Global Market, By Product, 2012 – 2017 ($Billion)  
Table - 4  Global Market, By Application, 2012 – 2017 ($Billion)  
Table - 5  Global Market, By Technology, 2012 – 2017 ($Billion)  
Table - 6  Insulin Analogs Market, By Geography, 2012 – 2017 ($Billion)    
Table - 7  Modified Epo Market, By Geography, 2012 – 2017 ($Billion)    
Table - 8  MAB Market, By Geography, 2012 – 2017 ($Billion)    
Table - 9  MAB Market, By Application, 2012 – 2017 ($Billion)     
Table - 10 Other Proteins Market, By Geography, 2012 – 2017 ($Billion)   
Table - 11 Diagnostic Proteins Market, By Geography, 2012 – 2017 ($Billion)   


List Of Figure (44 Figures)        

Fig - 1 Global Protein Engineering Market, 2012 – 2017 ($Billion)     
Fig - 2 Global Market, 2012 – 2017 ($Billion)     
Fig - 3 Global Market, By Geography, 2012 (%)     
Fig - 4 Growth Rate, By Geography, 2012 – 2017       
Fig - 5 Global Protein Engineering Market By Geography, 2012 – 2017 ($Billion)   
Fig - 6 Global Protein Engineering Market, By Product, 2012 (%)     
Fig - 7 Growth Rate, By Product, 2012 – 2017         
Fig - 8 Global Market, By Product, 2012 – 2017 ($Billion)    
Fig - 9 Global Protein Engineering Market, By Application, 2012 (%)     
Fig - 10 Growth Rate, By Application, 2012 – 2017       
Fig - 11 Global Market, By Application, 2012 - 2017 ($Billion)   
Fig - 12 Global Protein Engineering Market, By Technology, 2012 (%)     
Fig - 13 Growth Rate, By Technology, 2012 – 2017        
Fig - 14 Global Market, By Technology, 2012 – 2017 ($Billion)   
Fig - 15 Market Share Analysis         
Fig - 16 Insulin Analogs Market, By Geography, 2012        
Fig - 17 Insulin Analogs Market, By Geography, 2012 – 2017 ($Billion)     
Fig - 18 Market Share Analysis, Key Players, 2012       
Fig - 19 Market Share Analysis Of Epo, By Product, 2012      
Fig - 20 Modified EPO Market, By Geography, 2012       
Fig - 21 Modified EPO Market, By Geography, 2012 – 2017 ($Billion)     
Fig - 22 Market Share Analysis Of Engineered Therapeutic Proteins, By Product, 2012  
Fig - 23 MAB Market, By Geography, 2012        
Fig - 24 MAB Market, By Geography, 2012 – 2017 ($Billion)      
Fig - 25 MAB Market,By Application, 2012        
Fig - 26 MAB Market, By Application, 2012 – 2017 ($Billion)      
Fig - 27 Market Share Analysis Of Other Proteins, 2012      
Fig - 28 Other Proteins Market, By Geography, 2012       
Fig - 29 Other Proteins Market, By Geography, 2012 – 2017 ($Billion)     
Fig - 30 Diagnostic Proteins Market, By Geography, 2012      
Fig - 31 Diagnostic Proteins Market, By Geography, 2012 – 2017 ($Billion)    
Fig - 32 Product Pipeline Of Key Players        
Fig - 33 Growth Strategies          
Fig - 34 Amgen, Inc., Total Revenue          
Fig - 35 Biogen Idec, Inc., Total Revenue         
Fig - 36 Novartis Ag, Total Revenue          
Fig - 37 Glaxo Smithkline Plc, Total Revenue         
Fig - 38 Eli Lilly & Co., Total Revenue          
Fig - 39 Bristol Myers Squibb Co., Total Revenue        
Fig - 40 Johnson & Johnson , Total Revenue         
Fig - 41 Merck & Co., Inc., Total Revenue         
Fig - 42 Sanofi , Total Revenue          
Fig - 43 Pfizer, Inc., Total Revenue          
Fig - 44 Regeneron Pharmaceuticals, Inc. , Total Revenue        

Protein engineering is a method of improving or enhancing the properties of a protein by altering amino acid residues or an entire domain or synthetically linking to a chemical like poly-ethylene glycol. The method is extremely useful in the generation of novel proteins with stability, substrate specificity, binding affinity, catalytic activity, and folding/expression level.
Based on its applications, the market is segmented as therapeutics, diagnostics, and protein purification.The products segment is classified as monoclonal antibodies, insulin analogs, EPO, other proteins, diagnostics, and purification proteins. Technologies that are analyzed in the report include sequence modification/glycosylation, pegylation, display technologies, humanization technologies, hybrid technologies, and transgenic mice. The revenue and forecast for the growth of these technologies has been discussed in detail.

Protein engineering uses two approaches, namely, rational design and direct evolution to achieve its objectives. A combination of both these methods, termed as combinatorial method, has also been put to best use by scientists across the globe. Various techniques are employed by scientists employing either one or both approaches to generate a novel protein. Common techniques involve directed mutagenesis, in vitro display techniques, glycosylation using glycoengineered production systems, PEGylation, etc., These approaches are extremely challenging and pose potential risks, and cost constraints to the development of therapeutic proteins like antibodies, interferons, and growth factors. Advances in upcoming technologies like high throughput screening, lab automation, and structural biology have mitigated the risks, cost constraints, and are driving the market.

The global market was estimated at $100.1 billion in 2012, growing at a CAGR of 10.94% from 2012 to 2017; the therapeutic segment accounts for the major portion of the market. Under the therapeutic segment, 50% products are dominated by monoclonal antibodies with the top 10 fetching more than $1 billion in annual sales. Insulin analogs, modified version of EPO, Aranesp from Amgen and PEGylated interferons growth factors accounts for the rest.

Key players in the market include Genentech (U.S.), Amgen (U.S.), Roche (Switzerland), Eli Lilly (U.S.), Novartis (Switzerland),GlaxoSmithKline (U.K.),Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Merck (U.S.), Pfizer (U.S.), Sanofi (France), Affymax (U.S.), Biogen Idec, (U.S.), Medimmune (U.S.) Affimed (Germany), and Obodies (New Zealand).

North America is the major market, accounting for 42% of the market; it is expected to grow at a CAGR of 10%. Asia, however, is the fastest growing region with estimated CAGR of 13.5%.

Global Protein Engineering Market, 2012 - 2017 ($billion)

PROTEIN ENGINEERING MARKET

Source: MnM Analysis

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports